PHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas

American Journal of Dermatopathology

Volumn 34, Issue 3, 2012, Pages 266-269

  Schimming, Tobias T ^a   Grabellus, Florian ^a   Roßner, Mathias ^a   Pechlivanis, Sonali ^a   Sucker, Antje ^a   Bielefeld, Nicola ^a   Moll, Iris ^a   Schadendorf, Dirk ^a   Hillen, Uwe ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

AJCC; Melanoma; mitosis; mitotic rate; pHH3; phosphohistone H3; staging

Indexed keywords

ANTIBODY; KI 67 ANTIGEN; PHOSPHOHISTONE H3 ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; THIN MELANOMA; TRUNK; TUMOR LOCALIZATION; ULCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM STAGING; OBSERVER VARIATION; PHOSPHOPROTEINS; PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860367671     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31823135a3     Document Type: Article

References (24)

1. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;18:3668-3676.
2. Cook MG, Spatz A, Brocker EB, et al. Identification of histological features associated with metastatic potential in thin (,1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol. 2002;2:188-193.
3. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (, or =1.5 mm): identification of risk factors indicative of progression. Cancer. 1999;5:1067-1076.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;36:6199-6206.
5. Santillan AA, Messina JL, Marzban SS, et al. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol. 2010;3:481-486.
6. Shibata K, Ajiro K. Cell cycle-dependent suppressive effect of histone H1 on mitosis-specific H3 phosphorylation. J Biol Chem. 1993;25:18431-18434.
7. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;6:348-360.
8. Gurley LR, D'Anna JA, Barham SS, et al. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem. 1978;1:1-15.
9. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;11:1532-1536.
10. Kim YJ, Ketter R, Steudel WI, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;1:118-125.
11. Fukushima S, Terasaki M, Sakata K, et al. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol. 2009;2:51-57.
12. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol. 2010;7:650-654.
13. Angi M, Damato B, Kalirai H, et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol. 2009;89:e155-e160.
14. Bland JM, Altman DG. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med. 1990;5:337-340.
15. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-2205.
16. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;6:1488-1498.
17. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and surviving immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;2:117-122.
18. Rudolph P, Peters J, Lorenz D, et al. Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. Hum Pathol. 1998;11:1216-1222.
19. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;12:1571-1576.
20. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;5:657-664.
21. Glatz K, Hartmann C, Antic M, et al. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis. Am J Dermatopathol. 2010;7:643-649.
22. Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.
23. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;1:83-89.
24. Zhang X, Li X, Marshall JB, et al. Phosphoserines on maize centromeric histone H3 and histone H3 demarcate the centromere and pericentromere during chromosome segregation. Plant Cell. 2005;2:572-583. one H3 and histone H3 demarcate the centromere and pericentromere during chromosome segregation. Plant Cell. 2005;2:572-583.